The tweet was deleted by the author.
But we saved everything 🙂.
Rigel Pharmaceuticals has announced new presentations highlighting advancements in its hematology and oncology portfolio at the American Society of Hematology 2025 (ASH25) conference.
These presentations include updated data from the Phase 1b study evaluating R289 in patients with lower-risk Myelodysplastic Syndromes (MDS) and new data for olutasidenib in patients with relapsed or refractory mIDH1 Acute Myeloid Leukemia (AML). This reflects Rigel's ongoing commitment to delivering innovative therapeutic solutions in the field of hematology.
The latest updates might impact future treatment strategies and underline Rigel’s pursuit of innovation in addressing unmet medical needs in hematologic disorders.
Rigel’s latest clinical updates not only advance therapeutic possibilities in hematology but also build upon its established strategic focus on myelodysplastic syndromes, as emphasized in the company's dedicated push for increased MDS research. These efforts align with Rigel’s broader growth trajectory, detailed by its CEO in outlining the company's evolving biotech strategy within the sector.